4 Results for "

primary human β-cells

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "primary human β-cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-142295
CAS No.: 2561414-56-8
Purity:  98.32%
Target:  

DYRK

Research Areas:  

Metabolic Disease

GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-142295A
CAS No.: 2561414-57-9
Target:  

DYRK

Research Areas:  

Metabolic Disease

GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .
loading...
    loading...
Cat. No.: HY-19694
CAS No.: 1137359-47-7
Target:  

Insulin Receptor

Research Areas:  

Endocrinology

BRD7552, a potent PDX1 transcription factor inducer, upregulates PDX1 expression in both primary human islets and ductal cells, and induces epigenetic changes in the PDX1 promoter consistent with transcriptional activation. BRD7552 increases insulin expression. PDX1 is a key transcription factor involved in pancreas development and β cell function .
loading...
    loading...
Cat. No.: HY-170593
CAS No.: 3067202-14-3
Research Areas:  

Metabolic Disease

ChREBPα/14-3-3 regulator-1 is a molecular glue that selectively stabilizes ChREBPα/14-3-3 PPI, with an EC50 of 3.8 μM. ChREBPα/14-3-3 regulator-1 sequesters ChREBPα in the cytoplasm, inhibits ChREBPβ and TXNIP responses, reduces glucolipotoxicity-induced β-cell death, and maintains β-cell identity and function. ChREBPα/14-3-3 regulator-1 can be used in studies related to type 2 diabetes .
loading...
    loading...